Unlocking Type 1 Diabetes Data

JDRF partners with Tidepool on data integration software for better type 1 diabetes management JDRF is partnering with the non-profit organization Tidepool to develop a new data integration tool for people with type 1 diabetes (T1D) who use insulin pumps, continuous glucose monitors, or blood glucose meters. The new tool at the center of the […]

A Gut Reaction to Type 1 Diabetes

JDRF consortium defines roadmap for testing potential links between gut microbes and type 1 diabetes One of the first questions a person or parent of a child diagnosed with type 1 diabetes (T1D) often asks is, “what caused this?” While we have learned a lot about T1D, we still do not have a simple answer […]

A New Switch Hitter for Type 1 Diabetes Discovered

Pancreatic cells are more adaptable and possess a greater potential for self-healing than previously assumed For decades, the prevailing wisdom was that beta cells could not regenerate and that their loss in type 1 diabetes (T1D) was irreversible—the reason why people with T1D require insulin injections for life. JDRF-funded research is helping rewrite the textbook […]

Research Teamwork is Key to Curing Type 1 Diabetes

JDRF takes center stage at Capitol Hill briefing on accelerating biomedical research progress Richard A. Insel, M.D., JDRF’s Chief Scientific Officer, joined other research leaders at a Congressional briefing on, “How the Research-by-Consortia Model Will Lead to Faster Cures” held recently in Washington D.C. The briefing brought together biomedical leaders from foundations, industry, government, and […]

JDRF Partner ViaCyte to Immediately Initiate Type 1 Diabetes Clinical Trial

JDRF’s partner ViaCyte recently announced the U.S. Food and Drug Administration (FDA) is allowing them to move forward with a clinical trial of its innovative type 1 diabetes (T1D) encapsulated cell replacement therapy called VC-01™ product candidate. The company plans to immediately initiate the first ever clinical evaluation of a stem cell-derived islet replacement therapy […]

Oxygen – A Key Ingredient of Life

JDRF partners with Beta-O2 Technologies to develop a novel implantable encapsulation device for type 1 diabetes The dream for everyone with type 1 diabetes (T1D) is to permanently restore their body’s lost ability to produce insulin. This defines a cure for T1D and remains a top priority for JDRF. As we work towards this longer-term […]

Rebalancing the Immune System

Novel therapy to increase beneficial immune cells shows promise in pilot type 1 diabetes clinical study Type 1 diabetes (T1D) is caused when a person’s immune system mistakenly destroys their insulin-producing beta cells. How and why this misguided attack begins remains a mystery, but JDRF research has helped shed light on the disease process, opening […]

Potential Breakthrough in Encapsulation Technology

JDRF-funded researchers develop novel method of protecting islets for implantation into people with type 1 diabetes Pancreatic islet transplantation has restored insulin independence in some individuals with type 1 diabetes (T1D), but the procedure is not widely available due to the limited supply of donated islets and the need for strong immunosuppressive drugs to prevent […]

Cocktail Immune Therapy Beats Going Solo

New clinical results show positive effect of combination immune therapy for type 1 diabetes Type 1 diabetes (T1D) is caused when the immune system mistakenly attacks insulin-producing beta cells within the pancreas. While there have been numerous clinical studies using general immunotherapy to stop or slow the T1D attack, researchers have been generally disappointed with […]

Changing the Standard Management of Type 1 Diabetes

Adding novel therapy to an insulin regimen may allow for better glucose control and reduced insulin dosages Before insulin was discovered in 1921, people with type 1 diabetes (T1D) didn’t live very long. Its discovery was a great breakthrough and saved lives, but since then the basic management of T1D has continued to remain focused […]